For chronic weight management, adults may generally qualify for Tirzepatide if they have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition
Regular review ensures treatment remains appropriate and effective, with adjustments made according to symptom response and individual needs
Every major medical organization classifies obesity as a chronic, multifactorial disease
Print it, email it to yourself, or save it in your SingleCare account for easy access
The reduction in LFC was significantly correlated ( p 0.0006) with baseline LFC ( = 0.71), reductions in visceral adipose tissue (VAT) ( = 0.29), reductions in the transaminase liver enzyme ASAT ( = 033), and reductions in body weight ( p = 034) in the tirzepatide groups (54, 79)